Physician profile
Karla Guiab
NPI 1336792738
$1,657.24
in general payments reported to CMS, 2019-2025
6 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $561 · 2022: $229 · 2023: $372 · 2024: $249 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $661.55 | 2021-2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $384.49 | 2022-2025 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $242.83 | 2021-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $232.63 | 2023-2025 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $94.34 | 2021 | |
| Avanir Pharmaceuticals, INC. | $41.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Guiab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.